ZYDUSLIFE:NSE:NSE-Zydus Lifesciences Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1162.45

Change

0.00 (0.00)%

Market Cap

USD 1,085.57B

Volume

2.73M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-07 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-0.80 (-0.04%)

USD 4,554.89B
DIVISLAB:NSE Divi's Laboratories Limited

-4.75 (-0.09%)

USD 1,441.57B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+81.40 (+2.40%)

USD 1,154.88B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-102.40 (-1.52%)

USD 1,121.95B
MANKIND:NSE Mankind Pharma Ltd

+73.85 (+2.91%)

USD 1,033.59B
LUPIN:NSE Lupin Limited

+14.65 (+0.67%)

USD 998.11B
AUROPHARMA:NSE Aurobindo Pharma Limited

+7.45 (+0.51%)

USD 851.48B
ALKEM:NSE Alkem Laboratories Limited

+34.85 (+0.57%)

USD 740.60B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

+18.35 (+1.12%)

USD 473.60B
AJANTPHARM:NSE Ajanta Pharma Limited

-26.20 (-0.78%)

USD 418.19B

ETFs Containing ZYDUSLIFE:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 66.27% 96% N/A 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.27% 96% N/A 88% B+
Trailing 12 Months  
Capital Gain 99.65% 86% B+ 78% C+
Dividend Return 1.03% 62% D 59% D-
Total Return 100.68% 87% B+ 78% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 38.63% 64% D 55% F
Dividend Return 39.17% 63% D 55% F
Total Return 0.54% 54% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 38.31% 74% C 66% D+
Risk Adjusted Return 102.23% 88% B+ 88% B+
Market Capitalization 1,085.57B 96% N/A 95% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.